Molecular pathways: regulation and therapeutic implications of multidrug resistance

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Multidrug resistance (MDR) in human cancers is a significant clinical challenge.
• ABCB1 (MDR1) gene encodes P-glycoprotein (P-gp), a transporter crucial for drug distribution and MDR.
• Regulation of ABCB1 expression in cancer is complex and not fully understood in clinical settings.

Purpose of the Study:

• To elucidate the molecular signaling and epigenetic interactions governing ABCB1 expression in cancer.
• To focus on acquired ABCB1 expression linked to genomic instability.
• To identify potential translational targets for overcoming clinical MDR.

Main Methods:

• Review of molecular signaling pathways involved in ABCB1 regulation.
• Analysis of epigenetic modifications (DNA demethylation, histone acetylation) affecting ABCB1 promoters.
• Examination of genetic alterations (mutations, rearrangements) contributing to ABCB1 activation.

Main Results:

• Acquired ABCB1 expression is associated with cancer cell genomic instability.
• Mutations in tumor suppressor proteins like p53 can influence ABCB1 expression.
• Epigenetic modifications, including DNA demethylation and histone H3 acetylation, are key drivers of ABCB1 induction.
• A coordinated molecular network links genetic and epigenetic events to ABCB1 activation.

Conclusions:

• Understanding the interplay of genetic and epigenetic factors in ABCB1 regulation is crucial for combating MDR.
• Targeting these molecular networks offers promising strategies to overcome drug resistance in cancer patients.
• Mechanistic insights into ABCB1 activation provide novel therapeutic avenues for MDR treatment.